AIM ImmunoTech Inc. Reports Rights Offering Has Officially Expired With Early Proceeds Estimated At $1.8 Million

AIM ImmunoTech Inc., an immuno-pharma company developing its lead product Ampligen (rintatolimod) for late-stage pancreatic cancer, has shared the preliminary results of its previously announced rights offering. The offering expired on March 3, 2026, at 5:00 p.m. Eastern Time. Based on early estimates, the company expects total subscriptions of about $1.8 million. 

These results remain subject to final review and confirmation by AIM and its subscription agent, Broadridge Corporate Issuer Solutions, LLC. In this offering, each right allowed holders to purchase one Unit at a price of $1,000. Each Unit included one share of AIM’s Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants, which give holders the ability to purchase shares of the company’s common stock.

AIM anticipates that the offering will close on or around March 6, 2026, provided all closing conditions are met or waived. After the closing, the subscription agent will distribute the Preferred Stock and Warrants to investors who exercised their rights and paid the required subscription amount. These securities will be issued electronically, either through direct registration or via DTC. No physical certificates will be provided. Maxim Group LLC acted as the dealer-manager for the offering. Investors with questions or those who need the final prospectus can contact Maxim Group at its address on 300 Park Avenue in New York or reach the Syndicate Department by email or phone.

The company’s registration statement on Form S-1 (Registration No. 333-292085) was declared effective by the Securities and Exchange Commission on February 10, 2026. The official prospectus describing the terms of the rights offering is available on the SEC’s website. AIM also clarified that this announcement is not an offer to sell or solicit the purchase of any securities, nor will any sales occur in regions where such transactions would be unlawful without proper registration or qualification under applicable state or jurisdictional laws.